Arcus Biosciences (RCUS) Q1 2025 earnings summary

Executive summary

• Arcus Biosciences is advancing a broad late-stage oncology portfolio, prioritizing casdatifan, domvanalimab, and quemliclustat, with multiple pivotal Phase 3 trials targeting renal, lung, gastric, and pancreatic cancers.

• Strategic collaborations with AstraZeneca, Gilead, and Taiho enable cost-efficient development, expanded market access, and co-promotion rights.

• Casdatifan is advancing in clear cell RCC with multiple cohorts and combinations, aiming to displace TKIs in earlier lines.

• The company operates as a single segment, co-developing several programs with Gilead and retaining global rights to its HIF-2a program after Gilead's option expired.

• In Q1 2025, Arcus raised $150 million through an underwritten offering, with Gilead increasing its stake to 29.7%.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1 billion as of March 31, 2025, up from $992 million at 2024 year-end, bolstered by a $150 million equity financing in February 2025.

• Q1 2025 GAAP revenue was $28 million, down from $36 million in Q4 2024 and $145 million in Q1 2024, primarily due to lower collaboration revenue.

• Net loss for Q1 2025 was $112 million, compared to $4 million in Q1 2024.

• R&D expenses for Q1 2025 were $122 million, up from $111 million in Q4 2024 and $109 million in Q1 2024; G&A expenses were $28 million.

• Full-year 2025 GAAP revenue guidance is $75–90 million.

Outlook and guidance

• Cash runway is expected to fund operations through pivotal readouts for casdatifan, domvanalimab, and quemliclustat.

• R&D expenses projected to peak in 2025 and decline in subsequent years as late-stage programs advance.

• Multiple clinical data readouts and study initiations are planned for 2025 and 2026, including Phase 3 trials in kidney and gastrointestinal cancers.

• No revenue from product sales is expected in the near term; all revenue is from collaborations and licensing.